Harvard Pilgrim Health Care Home
  HPHConnect
 
  Learn more.
  Sign up for HPHConnect.
Medical Management
E-Transactions
HPHConnect
Pharmacy
For Your Patient
News Center
Network Matters
Newsletter Archives
Newsletter Registration
Newsroom
Office Support
Products
Provider Manual
Medicare Advantage
Research & Teaching
Resources & Links
 
Print    Text Size

Network Matters
News and Information for the
Harvard Pilgrim Health Care Network

April 2015

P&T Committee Updates 


At the March 2, 2015 meeting, the Harvard Pilgrim Pharmacy & Therapeutics Committee reviewed five medications and decided the following.

P&T Committee Review and Decisions

Name

Description and Indication

Decision

Bunavail (buprenorphine and naloxone) 

Bunavail is a buccal film indicated for the maintenance treatment of opioid dependence. 

Continued coverage at

  • Tier 3 for 3-Tier Premium formulary
  • Tier 4 for 4-Tier Premium formulary
  • Tier 3 on the 4-Tier Value formulary
  • Tier 4 on the 5-Tier Value formulary
  • Tier 4 on the Medicare Advantage formulary 

Jublia
(efinaconazole) 

Jublia is a topical azole antifungal used to treat toenail fungus (onychomycosis) due to Trichophyton rubrum and Trichophyton mentagrophytes.

Continued coverage at

Continued non-formulary status on

  • 4-Tier Value formulary
  • 5-Tier Value formulary
  • Medicare Advantage formulary

Kerydin (tavaborole) 

Kerydin is a topical oxaborale antifungal used to treat toenail fungus (onychomycosis) due to Trichophyton rubrum and Trichophyton mentagrophytes.

Continued coverage at

Continued non-formulary status on

  • 4-Tier Value formulary
  • 5-Tier Value formulary
  • Medicare Advantage formulary

Otezla (apremilast)

Otezla is a phosphodiasterase 4 (PDE-4) inhibitor indicated for the treatment of adult patients with active psoriatic arthritis and patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.

Continued coverage at

Continued non-formulary status on

  • 4-Tier Value formulary
  • 5-Tier Value formulary

Zubsolv (buprenorphine and naloxone) 

Zubsolv is a sublingual tablet indicated for the maintenance treatment of opioid dependence. 

Continued coverage at

  • Tier 3 for 3-Tier Premium formulary
  • Tier 4 for 4-Tier Premium formulary
  • Tier 3 on the 4-Tier Value formulary
  • Tier 4 on the 5-Tier Value formulary
  • Tier 3 on the Medicare Advantage formulary

Email this article to a colleague   


Network Matters Archives

Download printer-friendly version

HPHCURRENT EVENTS

Harvard Pilgrim 2015–2016 GIC Offerings

ACA Update: Fluoride Varnish and Hepatitis B Screenings

CLINICIAN CORNER

Prior Authorization of Select Surgical Procedures

Medical Policy for Esophagogastroduodenoscopy

Coverage for Reclast

P&T Committee Updates

Posttraumatic Stress Disorder’s Effect on Physical Health

OFFICE ASSISTANT

Reminder: Appointment Availability Standards

PUBLICATION INFORMATION

Eric H. Schultz,
President and Chief Executive Officer

Richard Weisblatt PhD,
Senior Vice President, Provider Network

Annmarie Dadoly,
Editor

Joseph O'Riordan,
Writer

Kristin Edmonston,
Production Coordinator